Cytosorbents Corp

NASDAQ:CTSO  
5.82
-0.22 (-3.64%)
Earnings Announcements

Cytosorbents Reports Q4 Revenue Of $12 Million

Published: 03/09/2021 21:34 GMT
Cytosorbents Corp (CTSO) - Q4 Revenue $12 Million Versus Refinitiv Ibes Estimate of $10.9 Million.
Believe That We Have Sufficient Cash to Fund Our Operations and Clinical Trial Activities Well Into Future.
Expect Our Q1 2021 Product Sales Will Exceed Product Sales Reported in Q1 of 2020.
Revenue is expected to be $11.96 Million
Adjusted EPS is expected to be -$0.09

Next Quarter Revenue Guidance is expected to be $11.12 Million
Next Quarter EPS Guidance is expected to be -$0.12

More details on our Analysts Page.